Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes

Eli Lil­ly’s re­ta­tru­tide, the in­cretin shot that has al­ready proven its ef­fec­tive­ness against oth­er as­sets on a cross-tri­al ba­sis, has ce­ment­ed its util­i­ty in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.